Head-to-head · Value Score
CoreAge Rx vs Pomegranate Health
Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, Pomegranate Health a 67. Here's who gives you the honest lower price — and where each one bites back.
CoreAge Rx
#1 · Grade A+ · Best Value
Est. first month
$99/mo
Save ~89% vs brand-namePomegranate Health
#293 · Grade C · Watch List
Est. first month
From $119/mo (Starter plan, dose not published, compounded)
Save ~91% vs brand-nameThe verdict
CoreAge Rx takes it on Value Score, 93 to 67 — an est. $99/mo first month, with no teaser step-up baked in. Pomegranate Health isn't out of it: Someone comparing low starter prices who can find them on the app site first.
CoreAge Rx is also our overall #1 pick across the whole deals ranking — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | CoreAge Rx | Pomegranate Health |
|---|---|---|
| Value Score | 93 (A+) | 67 (C) |
| Est. first month | $99/mo | From $119/mo (Starter plan, dose not published, compounded) |
| Save vs brand-name | ~89% | ~91% |
| Semaglutide | $99/mo | From $119/mo (Starter plan, dose not published, compounded) |
| Tirzepatide | $149/mo | From $149/mo (Starter plan, dose not published, compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
CoreAge Rx
The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.
Why it's a deal
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation — no lock-in
The fine print
- Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
Pomegranate Health
Pomegranate Health sells compounded semaglutide from $119 and tirzepatide from $149 on Starter plans, with no membership requirement and prices published on its app subdomain rather than its marketing site.
Why it's a deal
- Among the lowest starter prices tracked here at $119 semaglutide and $149 tirzepatide
- No membership requirement, with the price stated as the whole price
- One of the larger operations by its own count, citing more than 100,000 patients
- Publishes separate consent, HIPAA, terms and subscription documents rather than one catch-all page
The fine print
- The marketing site carries no price at all — the figures sit on a separate app subdomain, so a reader landing on the front page cannot compare anything
- Advertises "FDA-Regulated Pharmacies" without saying whether they are 503A, which state boards license, or 503B, which the FDA registers
- No dose is published against either Starter figure, so what the price buys is unknown
- The states served are not listed
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives ranking, and the same list for the other side is on alternatives to Pomegranate Health.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.